4th Quarter - Report

GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,490,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 20, 2023 $1,490,000 Replaced
4th Quarter - Amendment Apr 14, 2023 $1,490,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

International trade and protection of intellectual property; TRIPS Waiver; compulsory licensing and other IP issues in multiple countries.

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
CHARLES M. CLAPTON —
DAVID PULLIAM —
GRACE RODDEN —

Contacted: SENATE; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Security Council (NSC); State, Dept of (DOS); Commerce, Dept of (DOC); Patent & Trademark Office (PTO)

Health Issues HCR

Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.

LobbyistCovered position, as disclosed
BILL BODE —
MICHAEL D BOYD —
JENNIFER NIETO CAREY —
CHARLES M. CLAPTON —
ANNA GRIFFIN —
DAVID PULLIAM —
GRACE RODDEN —

Contacted: SENATE; State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Office of the Vice President of the United States; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); White House Office; Natl Institutes of Health (NIH); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.

LobbyistCovered position, as disclosed
BILL BODE —
MICHAEL D BOYD —
JENNIFER NIETO CAREY —
CHARLES M. CLAPTON —
ANNA GRIFFIN —
DAVID PULLIAM —
GRACE RODDEN —

Contacted: White House Office; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.

LobbyistCovered position, as disclosed
BILL BODE —
JENNIFER NIETO CAREY —
CHARLES M. CLAPTON —
DAVID PULLIAM —
GRACE RODDEN —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE; Patent & Trademark Office (PTO)

Budget/Appropriations BUD

Funding for Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocate on drug pricing proposals, including reconciliation legislation.

LobbyistCovered position, as disclosed
BILL BODE —
JENNIFER NIETO CAREY —
CHARLES M. CLAPTON —
DAVID PULLIAM —
GRACE RODDEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Legislative and regulatory proposals to change international and domestic corporate tax law and policy, including reconciliation legislation.

LobbyistCovered position, as disclosed
CHARLES M. CLAPTON —
DAVID PULLIAM —

Contacted: SENATE; Treasury, Dept of; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.